ECSP055575A - Uso de derivados de tio-oxindol en el tratamiento de enfermedades de la piel. - Google Patents

Uso de derivados de tio-oxindol en el tratamiento de enfermedades de la piel.

Info

Publication number
ECSP055575A
ECSP055575A EC2005005575A ECSP055575A ECSP055575A EC SP055575 A ECSP055575 A EC SP055575A EC 2005005575 A EC2005005575 A EC 2005005575A EC SP055575 A ECSP055575 A EC SP055575A EC SP055575 A ECSP055575 A EC SP055575A
Authority
EC
Ecuador
Prior art keywords
treatment
skin diseases
thio
oxindol derivatives
oxindol
Prior art date
Application number
EC2005005575A
Other languages
English (en)
Inventor
Andrew Fensome
Diane Deborah Harrison
Richarg Craing Winneker
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP055575A publication Critical patent/ECSP055575A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A61Q7/02—Preparations for inhibiting or slowing hair growth

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona métodos para el tratamiento de enfermedades de la piel, el cual incluye la administración a un mamífero de una composición que contiene un compuesto de fórmula I, o tautómeros del mismo, en un régimen donde la fórmula I es como se muestra y donde R1-R5 y Q1 son definidos como se describe aquí. Específicamente se describen métodos para el tratamiento del acné, el hirsutismo y una composición para acondicionar la piel.
EC2005005575A 2002-06-25 2005-01-25 Uso de derivados de tio-oxindol en el tratamiento de enfermedades de la piel. ECSP055575A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39191302P 2002-06-25 2002-06-25

Publications (1)

Publication Number Publication Date
ECSP055575A true ECSP055575A (es) 2005-04-18

Family

ID=30000776

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005575A ECSP055575A (es) 2002-06-25 2005-01-25 Uso de derivados de tio-oxindol en el tratamiento de enfermedades de la piel.

Country Status (17)

Country Link
US (1) US7115649B2 (es)
EP (1) EP1515680A4 (es)
JP (1) JP2005535625A (es)
KR (1) KR20050012831A (es)
CN (1) CN1662206A (es)
AR (1) AR040338A1 (es)
AU (1) AU2003258952A1 (es)
BR (1) BR0312092A (es)
CA (1) CA2489810A1 (es)
EC (1) ECSP055575A (es)
IL (1) IL165394A0 (es)
MX (1) MXPA04012418A (es)
NO (1) NO20045215L (es)
RU (1) RU2005101624A (es)
TW (1) TW200401637A (es)
WO (1) WO2004000227A2 (es)
ZA (1) ZA200410401B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6355648B1 (en) * 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
JP2005535623A (ja) * 2002-06-25 2005-11-24 ワイス ホルモン関連症状の治療における、チオ−オキシインドール誘導体の使用
EP1732921B1 (en) * 2004-04-08 2008-11-05 Wyeth Thioamide derivatives as progesterone receptor modulators
JP4950027B2 (ja) * 2004-04-08 2012-06-13 ワイス・エルエルシー チオアミド不純物を最小限に抑えるための方法
BRPI0510260A (pt) * 2004-04-27 2007-10-23 Wyeth Corp método para purificar um composto, e, kit farmacêutico
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
MY144968A (en) 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AR053710A1 (es) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
EP2073806B1 (en) 2006-10-12 2012-02-15 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
CN101636157A (zh) * 2007-01-12 2010-01-27 康乃尔研究基金会有限公司 作为抗菌干预的新型靶的腺苷酰环化酶
US9095578B2 (en) * 2007-01-12 2015-08-04 Cornell Research Foundation, Inc. Adenylyl cyclases as novel targets for the treatment of infection by eukaryotic pathogens
HRP20150882T1 (hr) 2008-10-17 2015-09-25 Xenon Pharmaceuticals Inc. Spirooksindolski spojevi i njihova upotreba kao terapijska sredstva
WO2010045197A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Spiro-oxindole compounds and their use as therapeutic agents
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
PE20170202A1 (es) 2009-10-14 2017-03-24 Xenon Pharmaceuticals Inc Metodos sinteticos para compuestos espiro-oxoindol
RU2596488C2 (ru) 2010-02-26 2016-09-10 Ксенон Фармасьютикалз Инк. Фармацевтические композиции спиро-оксиндольного соединения для местного введения и их применение в качестве терапевтических агентов
KR101278271B1 (ko) * 2011-08-02 2013-06-25 충남대학교산학협력단 인돌린-2-티온 유사체를 함유한 미백용 조성물
US9737522B2 (en) 2012-08-09 2017-08-22 Emory University NMDA receptor modulators and uses related thereto
AR103636A1 (es) 2015-02-05 2017-05-24 Teva Pharmaceuticals Int Gmbh Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US169198A (en) * 1875-10-26 Improvement in treating quicksilver-ore
US92711A (en) * 1869-07-20 e d w a r d s
EP0155934B1 (en) 1983-07-29 1989-12-06 Duke University Pharmaceutical compositions for treating androgen-related disorders in humans
DE4335876A1 (de) 1993-10-17 1995-04-20 Schering Ag Kombination von Progesteronantagonisten und Antiöstrogenen mit partialer agonistischer Wirkung für die Hormonsubstitutions-Therapie für peri- und postmenopausale Frauen
ES2258342T3 (es) 1998-10-23 2006-08-16 Aventis Pharma S.A. Preparaciones para aplicacion topica de sustancias que tienen efecto antiandrogenico.
IL143920A0 (en) 1998-12-31 2002-04-21 Sugen Inc 3-heteroarylidenyl-2-indolinone derivatives and pharmaceutical compositions containing the same
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
EP1206761B1 (en) 1999-08-26 2007-10-03 Automotive Systems Laboratory Inc. Magnetic sensor
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US7119207B2 (en) 2000-04-10 2006-10-10 Pfizer Inc Benzoamide piperidine containing compounds and related compounds
HUP0300413A2 (hu) 2000-04-10 2003-06-28 Pfizer Products Inc. Amidcsoportot viselő benzolgyűrűs csoporttal helyettesített piperidint tartalmazó és rokonszerkezetű vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
WO2006006555A1 (ja) * 2004-07-12 2006-01-19 Rohm Co., Ltd. 半導体発光素子

Also Published As

Publication number Publication date
ZA200410401B (en) 2006-05-31
WO2004000227A2 (en) 2003-12-31
JP2005535625A (ja) 2005-11-24
CN1662206A (zh) 2005-08-31
RU2005101624A (ru) 2005-06-27
EP1515680A2 (en) 2005-03-23
US20040006122A1 (en) 2004-01-08
AU2003258952A1 (en) 2004-01-06
WO2004000227A3 (en) 2004-04-08
IL165394A0 (en) 2006-01-15
EP1515680A4 (en) 2005-09-21
TW200401637A (en) 2004-02-01
AR040338A1 (es) 2005-03-30
US7115649B2 (en) 2006-10-03
NO20045215L (no) 2005-03-17
KR20050012831A (ko) 2005-02-02
MXPA04012418A (es) 2005-04-19
CA2489810A1 (en) 2003-12-31
BR0312092A (pt) 2005-03-22

Similar Documents

Publication Publication Date Title
CR10874A (es) Polimorfos de sal de succinato 2-[6-(3-amino-piperidin-1-ilo)-3 metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro benzonitrilo y metodos para el uso de los mismos
CO6761350A2 (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis
ECSP055572A (es) Derivados ciclotiocarbamativos como moduladores pr y el uso de los mismos en el tratamiento de enfermedades de la piel.
ECSP077324A (es) Amidas bicíclicas como inhibidores de cinasa
ECSP11011113A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
UY32882A (es) (heteroarilmetil) tiohidantoínas sustituidas
ECSP099387A (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogénesis
ECSP045474A (es) 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de 5-hidroxitriptamina-6
UY29938A1 (es) Derivados de pirido-, pirazo- y pirimido-pirimidina y su uso como inhibidores de mtor
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
PA8680701A1 (es) Derivados de oxindol
CR9881A (es) Polimorfos de la sal benzoato de 2-[[6-[(3r)-3amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-benzonitrilo y metodos de uso para los mismos
GT200500325A (es) Pirazolo-pirimidinas 1,4-sustituidas como inhibidores de quinasa
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
UY29099A1 (es) Fenilaminotiazoles sustituidos y su uso
GT200600517A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
PA8719401A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
ECSP045353A (es) Derivados de benzoxazinona, su preparación y aplicación como medicamentos
UY31305A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen.
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
UY28945A1 (es) Derivados de pirrolopiridina
BR0312092A (pt) Uso de derivados de tio-oxindol no tratamento de distúrbios da pele
UY28356A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos
NO20074780L (no) Heterocyklylamidsubstituerte imidazoler